Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma: multicohort, phase 2 keynote-087 study.
Moskowitz, C Zinzani, P Fanale, M Armand, P Johnson, N Ribrag, V von Tresckow, B Tomita, A Shipp, M
Moskowitz, C
Zinzani, P
Fanale, M
Armand, P
Johnson, N
Ribrag, V
von Tresckow, B
Tomita, A
Shipp, M
Citations
Altmetric:
Abstract
Description
Date
2016
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma: multicohort, phase 2 keynote-087 study. 2016, 101:44 Haematologica